ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics, the worldwide leader in hereditary cancer testing, announced today that it has officially launched its next-generation sequencing (NGS) renal, pancreatic and paraganglioma-pheochromocytoma (PGL/PCC) hereditary cancer panels. Ambry Genetics was the first commercial laboratory to launch hereditary cancer panels using NGS in 2012 with their comprehensive BreastNext, OvaNext, ColoNext and CancerNext…

Ambry Genetics Will Vigorously Defend Against BRCA1 and BRCA2 Gene Patent Infringement Suit Aliso Viejo, Calif. – July 10, 2013 – Ambry Genetics announced today that it intends to vigorously defend itself against the patent infringement suit filed yesterday in the United States District Court for the District of Utah by Myriad Genetics, the University…

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics announced today the launch of BRCA1 and BRCA2 analysis as part of their comprehensive cancer-testing menu. Two genes will be offered as a stand alone test comprising of full gene sequencing and deletion/duplication analyses in addition to being incorporated as part of multiple hereditary cancer panels that test cancer susceptibility…

An Innovative Service Laboratory with Clinical Diagnostic and Genomic Services Divisons, Ambry Genetics Serves the Genetics Industry through Friendly, Knowledgeable Client Services and High Quality R&D in a Cutting-Edge Environment Interview conducted by: Lynn Fosse, Senior Editor   CEOCFO: Mr. Dunlop, would you tell us the vision when you founded Ambry Genetics and where are you…

In early March, Ambry Genetics (Aliso Viejo, Calif.) reached the milestone of having sequenced 10,000 clinical diagnostic samples with next-generation sequencing (NGS) and processed 100,000 total NGS samples. Ambry has a proud history of being on the forefront of genetic testing, having been among the first purchasers of commercially available sequencing instruments back in 2007.…

Ambry Genetics Launches FFPE Somatic Variant Profiling Services Developed in Collaboration with Illumina Aliso Viejo, CA – April 4, 2013 – Ambry Genetics announced today that they have launched a somatic variant detection service, developed in collaboration with Illumina. This service complements Ambry’s extensive menu of next-generation sequencing services and portfolio of diagnostic genetic testing…

Ambry Genetics Achieves Company Milestone, Surpasses 10,000 Diagnostic and 100,000 Genomics Next Generation Sequencing Samples NGS technologies provide direct clinical benefit to patient care and expand genomics research. Aliso Viejo, CA – March 6, 2013 – Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced today that they have officially reached a…

NOTE: This article was written by Aaron Elliot, PhD, Director of Research and Development at Ambry Genetics. It originally ran in Medical Laboratory Observer, for viewable pdf click here. By Aaron Elliot, PhDPosted on: December 5th, 2012 Vol. 44 • Issue 12 • Page 28,29 Genetic testing has been a part of the clinical diagnostic strategy for more than…

ALISO VIEJO, Calif. – October 2, 2012 – Ambry Genetics (“Ambry”), a global leader in genetic services with a focus on clinical diagnostics and genomics, announces that chairman and CEO Charles Dunlop was honored with a “RARE Champion” award at Global Genes Project’s Champions of Hope Gala Event on the evening of Thursday, September 27 in Newport Beach,…

NOTE: This article was written by Elizabeth Chao, MD, Director of Translational Medicine at Ambry Genetics. It originally ran in Advance For The Administrators Of The Laboratory, viewable here. By Elizabeth Chao, MDPosted on: September 5, 2012 Vol. 21 • Issue 9 • Page 56 Focus On: Genetics In the field of molecular genetics, the ability to sequence…